Case Report
PDF Zotero Mendeley EndNote BibTex Cite

Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient

Year 2021, Volume 11, Issue 03, 170 - 173, 15.09.2021
https://doi.org/10.5799/jmid.994001

Abstract

We report a case of a 40-year-old male patient who developed a fever one week after recovering from severe COVID-19 illness that had needed treatment with injectable corticosteroids and Tocilizumab. The patient had had maculopapular lesions on his trunk months before contracting COVID-19, but the skin lesions progressed along with the post-covid fever. Detailed workup and biopsy from skin lesions on the face, trunk, and bone marrow revealed Histoplasmosis. This case highlights the possibility of flaring up of Histoplasmosis in COVID-19 patients who have been treated with immunosuppressants. In our case, the plausible reason for reactivation and growth of Histoplasma may be the suppression of IL6 action by Tocilizumab. It may be prudent to screen patients for Histoplasma and other fungal infections like aspergillus before administering an immune-suppressive regimen in patients with a moderate or severe COVID-19 illness. Urinary Histoplasma antigen may be used for screening in these patients. J Microbiol Infect Dis 2021; 11(3):170-173.

References

  • 1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-513.
  • 2. Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. COVID-19 Researchers Group. Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021; 27(1):83-88.
  • 3. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J Fungi 2020; 6(2):91.
  • 4. Wheat LJ. Diagnosis and management of Histoplasmosis. Eur J ClinMicrobiol Infect Dis 1989; 8:480-490.
  • 5. Minamoto GY, Rosenberg AS. Fungal Infections in patients with acquired immunodeficiency syndrome. Med Clin North Am 1997; 81:389-409.
  • 6. Cirillo-Hyland VA, Gross P. Disseminated histoplasmosis in a patient with acquired immunodeficiency syndrome. Cutis 1995;55(3):161-164.
  • 7. Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps. Curr Trop Med Rep 2014;1(2):119-128.
  • 8. Sayal S K, Prasad PS, Mehta A, Sanghi S. Disseminated Histoplasmosis: cutaneous presentation. Indian J Dermatol Venereol Leprol 2003; 69 (S1):90-91.
  • 9. Antinori S, Bonazzetti C, Gubertini G, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? AutoimmunRev 2020; 19(7):102564.
  • 10. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2(8):474-484.
  • 11. Bertolini M, Mutti MF, Barletta JA, et al. COVID-19 associated with AIDS-related disseminated Histoplasmosis: a case report. Int J STD AIDS 2020;31(12):1222-1224.
  • 12. Messina FA, Marin E, Caceres DH, et al. Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV-A Case Report from Argentina and Literature Review. J Fungi 2020; 6(4):275.
  • 13. Lane TE, Otero GC, Wu-Hsieh BA, Howard DH. Expression of inducible nitric oxide synthase by stimulated macrophages correlates with their antihistoplasma activity. Infect Immun 1994; 62(4):1478-9.
  • 14. Ranque S, Pelletier R, Michel-Nguyen A, Dromer F. Platelia Aspergillus assay for diagnosis of disseminated histoplasmosis. Eur J ClinMicrobiol Infect Dis. 2007; 26(12):941-943.
  • 15. Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRadPlatelia Aspergillus enzymeimmunoassay. Clin Vaccine Immunol 2007; 14:638-640.

Details

Primary Language English
Subjects Health Care Sciences and Services
Journal Section Case Report
Authors

Premmapassan KRISHNAMURTHY This is me
Dr. Ram Manohar Lohia Hospital, New Delhi, India
India


Brijesh SHARMA This is me
Dr. Ram Manohar Lohia Hospital, New Delhi, India
India


Desh DEEPAK This is me
Dr. Ram Manohar Lohia Hospital, New Delhi, India
India


Shailaja SHUKLA This is me
Dr. Ram Manohar Lohia Hospital, New Delhi, India
India


Vishakha ARYA This is me
Dr. Ram Manohar Lohia Hospital, New Delhi, India
India


Anuradha CHOWDHARY This is me
Dr. Ram Manohar Lohia Hospital, New Delhi, India
India

Publication Date September 15, 2021
Published in Issue Year 2021, Volume 11, Issue 03

Cite

Bibtex @case report { jmid994001, journal = {Journal of Microbiology and Infectious Diseases}, issn = {2146-3158}, eissn = {2146-9369}, address = {}, publisher = {Sağlık Araştırmaları Derneği}, year = {2021}, volume = {11}, pages = {170 - 173}, doi = {10.5799/jmid.994001}, title = {Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient}, key = {cite}, author = {Krıshnamurthy, Premmapassan and Sharma, Brijesh and Deepak, Desh and Shukla, Shailaja and Arya, Vishakha and Chowdhary, Anuradha} }
APA Krıshnamurthy, P. , Sharma, B. , Deepak, D. , Shukla, S. , Arya, V. & Chowdhary, A. (2021). Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient . Journal of Microbiology and Infectious Diseases , 11 (03) , 170-173 . DOI: 10.5799/jmid.994001
MLA Krıshnamurthy, P. , Sharma, B. , Deepak, D. , Shukla, S. , Arya, V. , Chowdhary, A. "Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient" . Journal of Microbiology and Infectious Diseases 11 (2021 ): 170-173 <https://dergipark.org.tr/en/pub/jmid/issue/64866/994001>
Chicago Krıshnamurthy, P. , Sharma, B. , Deepak, D. , Shukla, S. , Arya, V. , Chowdhary, A. "Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient". Journal of Microbiology and Infectious Diseases 11 (2021 ): 170-173
RIS TY - JOUR T1 - Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient AU - Premmapassan Krıshnamurthy , Brijesh Sharma , Desh Deepak , Shailaja Shukla , Vishakha Arya , Anuradha Chowdhary Y1 - 2021 PY - 2021 N1 - doi: 10.5799/jmid.994001 DO - 10.5799/jmid.994001 T2 - Journal of Microbiology and Infectious Diseases JF - Journal JO - JOR SP - 170 EP - 173 VL - 11 IS - 03 SN - 2146-3158-2146-9369 M3 - doi: 10.5799/jmid.994001 UR - https://doi.org/10.5799/jmid.994001 Y2 - 2021 ER -
EndNote %0 Journal of Microbiology and Infectious Diseases Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient %A Premmapassan Krıshnamurthy , Brijesh Sharma , Desh Deepak , Shailaja Shukla , Vishakha Arya , Anuradha Chowdhary %T Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient %D 2021 %J Journal of Microbiology and Infectious Diseases %P 2146-3158-2146-9369 %V 11 %N 03 %R doi: 10.5799/jmid.994001 %U 10.5799/jmid.994001
ISNAD Krıshnamurthy, Premmapassan , Sharma, Brijesh , Deepak, Desh , Shukla, Shailaja , Arya, Vishakha , Chowdhary, Anuradha . "Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient". Journal of Microbiology and Infectious Diseases 11 / 03 (September 2021): 170-173 . https://doi.org/10.5799/jmid.994001
AMA Krıshnamurthy P. , Sharma B. , Deepak D. , Shukla S. , Arya V. , Chowdhary A. Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient. J Microbil Infect Dis. 2021; 11(03): 170-173.
Vancouver Krıshnamurthy P. , Sharma B. , Deepak D. , Shukla S. , Arya V. , Chowdhary A. Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient. Journal of Microbiology and Infectious Diseases. 2021; 11(03): 170-173.
IEEE P. Krıshnamurthy , B. Sharma , D. Deepak , S. Shukla , V. Arya and A. Chowdhary , "Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient", Journal of Microbiology and Infectious Diseases, vol. 11, no. 03, pp. 170-173, Sep. 2021, doi:10.5799/jmid.994001